Cognition Therapeutics, Inc. (CGTX)
Last updated: 2026-10-21 09:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Cognition Therapeutics, Inc. (CGTX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.75, with a market capitalization of $69.17M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.55 to $1.93. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$69.17M | |
$0.75 | |
$13.80 | |
$0.22 | |
$0.73 | |
1.50K | |
511.89K | |
-- | |
$1.93 | |
$0.55 | |
-- | |
-- |
Cognition Therapeutics, Inc. (CGTX) Pre-Market Stock Price
Cognition Therapeutics, Inc. (CGTX) is trading at $0.75 in pre-market trading as of 2026-10-21 08:59:00, up 2.75% ($0.02) from the previous close of $0.73
Pre-market trading shows how investors are pricing CGTX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Cognition Therapeutics, Inc. (CGTX) 7-Day Stock Price Change
Over the past seven days, Cognition Therapeutics, Inc. (CGTX) moved from $0.86 to $0.75, representing a decline of 12.01% ($0.10).
The stock traded between $0.71 and $0.93 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 979.47 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
CGTX 52-Week Price Position
Position in Range: 14.8%
CGTX is currently trading at $0.75, placing it 14.8% of the way from its 52-week low of $0.55 to its 52-week high of $1.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Cognition Therapeutics, Inc. (CGTX)?
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Cognition Therapeutics, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Cognition Therapeutics, Inc. (CGTX) Stock on MEXC
Eligible investors can buy real shares of Cognition Therapeutics, Inc. (CGTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Cognition Therapeutics, Inc. (CGTX) stock price today?
2.Is CGTX stock going up or down today?
3.What is CGTX pre-market price?
4.What is CGTX after-hours price?
5.Is CGTX stock trading now?
6.Where does CGTX sit relative to its 52-week high and low?
7.What sector is Cognition Therapeutics, Inc. in?
8.What is Cognition Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is CGTX valued in terms of P/E ratio and EPS?
10.Does Cognition Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
CGTX Stock Calculator
Estimate the value between CGTX shares and USD.
CGTX Shares to USD
1.00 CGTX shares = 0.754 USD
Calculations are estimates based on the latest available price and are for reference only.


